Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05842603 · ClinicalTrials.gov registry record · NA

I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

A NA study of Leukemia and Myeloproliferative Disorders, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
3
Study locations

NCT05842603: Recruiting NA study of Leukemia and Myeloproliferative Disorders, sponsored by Massachusetts General Hospital.

NCT05842603 is a NA study of Leukemia and Myeloproliferative Disorders that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05842603, a NA study of Leukemia and Myeloproliferative Disorders, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
3
Study locations

Study Summary

The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods. The name of the intervention used in this research study is: Cardiac Lifestyle Program (a 12-week, tailored nutrition and physical activity program)

Primary Outcome

Feasibility of this pilot trial will be measured by the number of participants that complete at least 9 weeks of the exercise program. This trial will be considered feasible if at least 70% (≥21) of participants complete the program. Completion rates will be measured with a 95% confidence interval for the adherence proportion calculated by exact binomial method.

Interventions

  • BEHAVIORAL Cardiac Lifestyle Program

Study Locations (3)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston
  • Massachusetts General Hospital Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-03-01
Est. Completion 2027-01-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT05842603 shows while recruiting

NCT05842603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Cardiac Lifestyle Program is the first listed.

NCT05842603 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05842603 about?

NCT05842603 is a clinical study titled "I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients". The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods. The name of the intervention used in this research study i...

What is the current status of trial NCT05842603?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-03-01. Estimated completion is 2027-01-01.

What conditions does trial NCT05842603 study?

This clinical trial studies the following conditions: Leukemia, Myeloproliferative Disorders.

What interventions are being tested in trial NCT05842603?

The interventions under investigation include: Cardiac Lifestyle Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT05842603?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05842603 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05842603's enrollment target sits among peer trials

30 159th of 233 higher than 69 of 233 other Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05842603, the US trial registry maintained by the National Library of Medicine. NCT05842603 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.